Literature DB >> 2333742

Incidence of Clostridium difficile in hospitalized children. A prospective study.

M Tvede1, P O Schiøtz, P A Krasilnikoff.   

Abstract

A total of 394 children, aged 0-14 years, referred to a paediatric department were investigated for the occurrence of Clostridium difficile, its cytotoxin in faeces, and its clinical significance in a prospective study over one year. Of the children in the investigation, 337 suffered from gastrointestinal diseases or had been treated with antibiotics prior to the investigation. Twenty-four percent of these children had Cl. difficile in one or more faecal samples and toxin was demonstrated in half of these patients. In 18/148 (12%) of the patients with acute gastroenteritis Cl. difficile was isolated as the only pathogen. In contrast, among 57 control children with no gastrointestinal symptoms and no prior antibiotic treatment significantly fewer harboured Cl. difficile (p less than 0.01). Cl. difficile was isolated with similar frequency in children with or without prior antibiotic treatment. Isolation of Cl. difficile was significantly higher in patients under one year of age (p less than 0.001). In 78% of the patients with Cl. difficile the bacteria were found in faeces during the initial two days of hospitalization indicating that most of the cases were community acquired. The occurrence of Cl. difficile was not influenced by seasonal variation and the distribution between sexes was equal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2333742     DOI: 10.1111/j.1651-2227.1990.tb11459.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  7 in total

1.  Prevalence and genotypic characteristics of Clostridium difficile in a closed and integrated human and swine population.

Authors:  Keri N Norman; H Morgan Scott; Roger B Harvey; Bo Norby; Michael E Hume; Kathleen Andrews
Journal:  Appl Environ Microbiol       Date:  2011-07-01       Impact factor: 4.792

2.  The incidence and clinical symptomatology of Clostridium difficile infections in a community setting in a cohort of Danish patients attending general practice.

Authors:  L M Søes; H M Holt; B Böttiger; H V Nielsen; M Torpdahl; E M Nielsen; S Ethelberg; K Mølbak; V Andreasen; M Kemp; K E P Olsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-19       Impact factor: 3.267

Review 3.  Co-infection as a confounder for the role of Clostridium difficile infection in children with diarrhoea: a summary of the literature.

Authors:  H de Graaf; S Pai; D A Burns; J A Karas; D A Enoch; S N Faust
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-01       Impact factor: 3.267

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

5.  How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex PCR-based detection.

Authors:  C Stockmann; M Rogatcheva; B Harrel; M Vaughn; R Crisp; M Poritz; S Thatcher; E K Korgenski; T Barney; J Daly; A T Pavia
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

6.  Heterogeneity of Clostridium difficile isolates from infants.

Authors:  A Collignon; L Ticchi; C Depitre; J Gaudelus; M Delmée; G Corthier
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

7.  Clinical significance of Clostridium difficile and its toxins in faeces of immunocompromised children.

Authors:  M J Wolfhagen; K Meijer; A C Fluit; R Torensma; R A Bruinsma; A Fleer; J Verhoef
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.